About This Content

This section provides supplementary clinical information for the Dalbavancin Dose Calculator. It covers the calculator's outputs, dosing principles for Acute Bacterial Skin and Skin Structure Infections (ABSSSI), and other practical considerations. Always consult the full prescribing information and use independent clinical judgment.

Outputs Explained

The calculator provides the following key outputs based on your inputs:

  • Recommended Dose: The precise dalbavancin dose in milligrams (mg) for either the single-dose or two-dose regimen.
  • Dosing Schedule: Clarifies whether the dose is a one-time infusion or split into an initial dose and a second dose one week later.
  • Renal Adjustment Status: Indicates if a dose reduction was applied due to severe renal impairment (CrCl < 30 mL/min).
  • Administration Notes: Includes standard guidance on infusion time (30 minutes) and reconstitution.

How to Use the Calculator

  1. Select Input Method: Choose whether to calculate Creatinine Clearance (CrCl) using the Cockcroft-Gault formula or to manually enter a known CrCl value.
  2. Enter Patient Data: If calculating, provide the patient's weight, age, sex, and serum creatinine (SCr). Ensure you select the correct units (kg/lbs and mg/dL/µmol/L).
  3. Select Dosing Regimen: Choose between the single-dose (1500 mg) or two-dose (1000 mg then 500 mg) regimen.
  4. Indicate Hemodialysis Status: Check the box if the patient is on regularly scheduled hemodialysis, as this affects dosing recommendations.
  5. Calculate: Click the "Calculate Dose" button to see the results.

Dosing Overview for ABSSSI

Dalbavancin is a long-acting lipoglycopeptide antibiotic approved for ABSSSI. Dosing is dependent on renal function.

Standard Dosing (CrCl ≥ 30 mL/min)

  • Single-Dose Regimen: A single intravenous infusion of 1500 mg.
  • Two-Dose Regimen: An initial intravenous infusion of 1000 mg, followed one week later by a second infusion of 500 mg.

Renal Impairment Dosing (CrCl < 30 mL/min, not on hemodialysis)

  • Single-Dose Regimen: A single intravenous infusion of 1125 mg.
  • Two-Dose Regimen: An initial intravenous infusion of 750 mg, followed one week later by a second infusion of 375 mg.
Patients on Hemodialysis: No dose adjustment is required for patients on regularly scheduled hemodialysis. Dalbavancin can be administered without regard to the timing of dialysis.

Switching To Dalbavancin

Dalbavancin's long half-life makes it a valuable option for completing therapy in an outpatient setting, potentially reducing hospital length of stay. Patients with ABSSSI who have been stabilized on initial intravenous antibiotics (e.g., vancomycin, daptomycin) can be switched to dalbavancin to facilitate discharge. The timing of the first dalbavancin dose should be coordinated to replace the next scheduled dose of the prior antibiotic.

Missed Dose Information

For the two-dose regimen, the second dose is administered one week (7 days) after the first. If a patient misses the second scheduled dose, it should be administered as soon as possible. The timing of subsequent doses, if any were planned (off-label), would need to be re-evaluated. For the single-dose regimen, this concern is not applicable.

Safety Alerts

  • Hypersensitivity Reactions: Serious hypersensitivity (anaphylactic) and skin reactions have been reported. Discontinue dalbavancin if a reaction occurs.
  • Infusion-Related Reactions: Rapid intravenous infusion can cause reactions similar to "Red Man Syndrome," including flushing, urticaria, and pruritus. Administering the infusion over 30 minutes minimizes this risk.
  • Hepatic Effects: Elevations in liver enzymes (ALT) have been observed. Monitor liver function as clinically indicated.
  • Clostridioides difficile-Associated Diarrhea (CDAD): As with other antibiotics, CDAD has been reported and can range in severity.

Frequently Asked Questions

1. Why did the calculator recommend a 1125 mg dose instead of 1500 mg?

A dose of 1125 mg is recommended when the single-dose regimen is selected for a patient with severe renal impairment (CrCl < 30 mL/min) who is not on hemodialysis. This is a 25% reduction from the standard 1500 mg dose.

2. What formula does the calculator use for CrCl?

The calculator uses the standard Cockcroft-Gault equation to estimate creatinine clearance when the "Calculate" option is selected.

3. Is a dose adjustment needed for patients on hemodialysis?

No. According to the prescribing information, no dose adjustment is necessary for patients receiving regularly scheduled hemodialysis. The calculator will recommend the standard dose if the hemodialysis box is checked, regardless of the calculated CrCl.

4. Can I use this calculator for pediatric patients?

No. This calculator is designed for adult patients (age ≥ 18) only. Dosing for pediatric patients has not been established in the same manner.

5. How is dalbavancin administered?

Dalbavancin must be administered via intravenous (IV) infusion over 30 minutes. It should not be given as an IV push or bolus.

6. Why are there two different dosing regimens (single-dose vs. two-dose)?

Both regimens have been shown to be effective for ABSSSI. The choice may depend on institutional protocols, patient logistics, and prescriber preference. They provide similar drug exposure over the treatment period.

7. What if my patient's serum creatinine is in µmol/L?

The calculator includes a unit toggle. Select "µmol/L" next to the Serum Creatinine input field, and the tool will automatically convert the value to mg/dL for the calculation.

8. How does patient sex affect the calculation?

In the Cockcroft-Gault formula, the result is multiplied by 0.85 for female patients to account for lower muscle mass on average, which influences creatinine generation.

References

  1. DALVANCE® (dalbavancin) for injection, for intravenous use. U.S. Prescribing Information. FDA.
  2. Xydalba (dalbavancin) Summary of Product Characteristics (SmPC). European Medicines Agency.
  3. Dunne, M. W., Puttagunta, S., Sprenger, C. R., Rubino, C., Van Wart, S., & Baldassarre, J. (2016). A randomized, double-blind study of dalbavancin versus vancomycin for treatment of adolescents and children with acute bacterial skin and skin structure infection. The Pediatric infectious disease journal, 35(5), 503–508. (Note: Although this reference is pediatric, it provides background on the drug's use and properties).
  4. Boucher, H. W., Wilcox, M., Dube, G., et al. (2014). Once-Weekly Dalbavancin versus Twice-Daily Vancomycin for Acute Bacterial Skin and Skin Structure Infections. New England Journal of Medicine, 370(23), 2169-2179.
PRO
Ad-Free Access
$3.99 / month
  • ✓ No Interruptions
  • ✓ Faster Page Loads
  • ✓ Support Content Creators
Subscribe Now